drugset / Trial / NCT00939172
TTP607 in Refractory Solid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of TTP607 that can be given to patients with a solid tumor or lymphoma. The safety of TTP607 will also be studied. Researchers will also do pharmacokinetic (PK) testing of TTP607. PK testing measures the amount of a drug in the body at different time points.
Timeline
- Start
- 2010-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TTP607 | Unknown | 3.3 mg/m2 | — |